Many other factors may influence the frequency of the valves in the axillary vein. (J Vase Surg 2011;54:70S-6S.)”
“The cooperative organization of enzymes by cells is a key feature for the efficiency of living systems. In the field of nanotechnologies, effort currently aims at mimicking this natural organization. Nanoscale resolution and high-registration alignment are necessary to control enzyme distribution in nano-containers or on the surface of solid
supports. Virus capsid self-assembly is driven by precise supramolecular combinations of protein monomers, which have made them attractive building blocks to engineer enzyme nano-carriers (ENCs). We discuss some examples of what in our opinion constitute the latest advances in the use of plant viruses, bacteriophages and virus-like particles (VLPs) as nano-scaffolds for enzyme selection, enzyme confinement and patterning, 4-Hydroxytamoxifen nmr phage therapy, raw material 4SC-202 datasheet processing, and single molecule enzyme kinetics studies.”
“Prostate cancer (PCa) is the most common cancer diagnosis and the second most common cause of cancer-related deaths in men. Currently, serum prostate-specific antigen (PSA) is the only biomarker widely used in the diagnosis and management of patients with PCa. However, PSA lacks diagnostic sensitivity and specificity leading to false-negative and false-positive test results. PSA cannot distinguish indolent from aggressive disease, leading to many patients being over-treated with associated
side-effects. Further-more, PSA is unable to identify which tumors are likely to become unresponsive to treatment at an early stage. Thus, there is an urgent need for clinically validated biomarkers which will improve the diagnosis
and management of PCa. Given the heterogeneity of PCa it is likely that a panel of biomarkers will be required. in the quest for PCa biomarkers, a wide range of samples including urine, serum, tissues, and cell lines have been studied using proteomic approaches such as 2-DE, SELDI-TOF, SILAC, ICAT, iTRAQ, and MALDI-IMS. The value of these technologies, and other emerging platforms such as selected reaction monitoring (SRM) selleck and multiple reaction monitoring (MRM), are discussed in the context of biomarker discovery, validation and addressing the “”bottle-necks”" that exist prior to clinical translation.”
“Thoracic venous aneurysm is an extremely rare condition. This report describes the case of a 70-year-old woman with a left brachiocephalic venous aneurysm that caused recurrent nerve paralysis. Contrast-enhanced computed tomography and venography revealed a venous aneurysm, 4 cm in size, located adjacent to the venous angle. Anticoagulation therapy was started, and 1-1/2 months later, the aneurysm greatly decreased in size and showed marked calcification along its periphery. Venous aneurysms that shrink after anticoagulation therapy are exceptionally rare. The clinical features of this condition have been briefly reviewed. (J Vase Surg 2011;54:77S-9S.